Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 10 May 21 424B4 Prospectus supplement with pricing info
- 7 May 21 EFFECT Notice of effectiveness
-
3 May 21 S-1/A IPO registration (amended)
- 16 Apr 21 S-1 IPO registration
TRML similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-255316 on Form S-1 of our report dated February 26, 2021, (May 3, 2021, as to the effects of the subsequent events described in Note 16) relating to the financial statements of Talaris Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP |
Boston, Massachusetts May 3, 2021 |